Angiotensin receptor blockers and cancer – Relationship dismissed by VALUE data while waiting for EMA and FDA reports

Sverre E. Kjeldsen Department of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway

Thomas Hedner Department of Medicine, University of Göteborg, Sahlgrenska Academy, Göteborg, Sweden

Suzanne Oparil Vascular Biology and Hypertension Program, University of Alabama, Birmingham, Alabama, USA

Krzysztof Narkiewicz Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland

References

Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol Online June 14, 2010 DOI:10.1016/S1470-2045(10)70106-6.
Google Scholar
Nissen SE. Comment. Angiotensin-receptor blockers and cancer: Urgent regulatory review needed. Lancet Oncol Online June 14, 2010 DOI:10.1016/S1470-2045(10)70142-X.
Google Scholar
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004; 363:2022–2031.
PubMed Web of Science ®Google Scholar
Julius S, Kjeldsen SE, Weber M. Angiotensin receptor blockade and the risk of cancer: Omission of VALUE Trial data Invalidates Conclusions. Lancet Oncol. 2010; 11:820–1.
PubMed Web of Science ®Google Scholar
Hedner T, Hansson L, Jern S. Is hypertension a risk factor for cancer? Blood Press. 1997;6:132–133.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Angiotensin receptor blockers and cancer – Relationship dismissed by VALUE data while waiting for EMA and FDA reports

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Angiotensin receptor blockers and cancer – Relationship dismissed by VALUE data while waiting for EMA and FDA reports

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date